[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"logopenic-progressive-aphasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:logopenic-progressive-aphasia":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,77,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100557453","early-phase-1-transcranial-magnetic-stimulation-treatment-for-alzheimers-disease-100557453",false,"NCT06538311","Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease","Neuromodulation of Brain Function in Alzheimer's Disease and Related Dementias","Inclusion Criteria:\n\n1. Between the ages of 40-99\n2. Native English speakers\n3. Willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points\n4. Patients with PPA will be asked to bring a study partner to all visits\n5. Patients with very mild or mild PPA, patients with amnestic mild cognitive impairment and cognitively unimpaired participants with preclinical AD will be included.\n\nExclusion Criteria:\n\n1. History of head trauma involving loss of consciousness or alteration in consciousness\n2. Another major neurologic or psychiatric condition\n3. Known presence of a structural brain lesion (e.g. tumor, cortical infarct)\n4. Any contraindication to MRI, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body\n5. Longstanding premorbid history (i.e. longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed\n6. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol.\n7. Unwilling to return for follow-up, undergo neuropsychological testing, TMS, and MR imaging\n8. History of unprovoked seizures (i.e., seizures that occur in the absence of a clear provocation such as hyponatremia, hypoglycemia, etc.).\n9. Subjects who have a first degree relative (e.g., father, mother or sibling) with a seizure disorder.\n10. Subjects currently taking, or plan to take, medications which are highly epileptogenic. These include: clozapine, high doses of bupropion (i.e., greater than 400mg daily), diphenhydramine, cyclosporine, isoniazid, imipenem, chloroquine, tramadol and theophylline.\n11. Subjects actively on anti-amyloid treatments. This is because they are at risk for bleeding due to amyloid-related imaging abnormalities (ARIA) that could provoke seizures.",true,"ALL","40 Years","99 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI).\n\nThis study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls memory. Changes resulting from this stimulation will be measured with behavioral tests of memory and general cognition, as well as by taking images of your brain with Magnetic Resonance Imaging (MRI).\n\nParticipants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.",[28,29,30,31],"Alzheimer Disease","Mild Cognitive Impairment","Logopenic Progressive Aphasia","Amnestic Symptoms",[33],"Transcranial Magnetic Stimulation","RECRUITING","2026-05-05",{"date":37,"type":38},"2026-05-06","ACTUAL",{"date":40,"type":38},"2023-05-01",{"date":42,"type":22},"2027-03-31",{"name":44,"class":45},"Massachusetts General Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100468946","phase-2-transcranial-direct-current-stimulation-in-the-treatment-of-primary-progressive-aphasia-100468946","NCT05386394","Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia","Phase II Clinical Trial of Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia","Inclusion Criteria:\n\n* Presence of aphasia attributable to non-fluent PPA or logopenic PPA\n* High school education (or more)\n* Between the ages of 50 and 90\n* Must be able to understand the nature of the study and give informed consent\n\nExclusion Criteria:\n\n* Cognitive impairment of sufficient severity to preclude giving informed consent (Mini Mental State Examination \\[MMSE\\] less than 15)\n* Any unrelated neurologic or physical condition that impairs communication ability\n* History of unrelated neurological conditions, including but not limited to traumatic brain injury (TBI), stroke, or small vessel disease, that has resulted in a neurologic deficit\n* Any additional neurological condition that would likely reduce the safety of study participation, including central nervous system (CNS) vasculitis, intracranial tumor, intracranial aneurysm, multiple sclerosis, or arteriovenous malformations\n* A medically unstable cardiopulmonary or metabolic disorder\n* Individuals with pacemakers or implantable cardiac defibrillators\n* Terminal illness associated with survival of less than 12 months\n* Major active psychiatric illness that may interfere with required study procedures or treatments, as determined by the enrolling physician\n* Current abuse of alcohol or drugs, prescription or otherwise\n* Participant in another drug, device, or biologics trial within 30 days prior to enrollment\n* Nursing a child, pregnant, or intending to become pregnant during the study\n* Left-handedness\n\nExclusion for tDCS, specifically:\n\n* History of spontaneous or partial complex seizures or unexplained loss of consciousness within 6 months of enrollment\n* Subjects with metallic objects in the face or head other than dental apparatus, such as braces, fillings, or implants\n* Subjects with previous craniotomy or any breach in the skull\n\nExclusion for MRI, specifically:\n\n* Presence of any of the following devices: cardiac pacemaker, other pacemakers (for carotid sinus, insulin pumps, nerve stimulators, lead wires or similar wires), optic implant, implanted cardiac defibrillator, aneurysm clip, any electronically\u002Fmagnetically\u002Fmechanically activated implant, ferromagnetic implants (coils, filters, stents; metal sutures or staples)\n* Presence of any of the following: pregnancy, claustrophobia, metal in eye or orbit, tattooed eyeliner","50 Years","90 Years",{"count":57,"type":22},180,[59],"PHASE2","While many have strongly suggested that transcranial direct current stimulation (tDCS) may represent a beneficial intervention for patients with primary progressive aphasia (PPA), this promising technology has not yet been applied widely in clinical settings. This treatment gap is underscored by the absence of any neurally-focused standard-of-care treatments to mitigate the devastating impact of aphasia on patients' family, work, and social lives. Given that tDCS is inexpensive, easy to use (it is potentially amenable to home use by patients and caregivers), minimally invasive, and safe there is great promise to advance this intervention toward clinical use. The principal reason that tDCS has not found wide clinical application yet is that its efficacy has not been tested in large, multi-center, clinical trials. In this study, scientists in the three sites that have conducted tDCS clinical trials in North America-Johns Hopkins University and the University of Pennsylvania in the US, and the University of Toronto in Canada, will collaborate to conduct a multi-site, Phase II clinical trial of tDCS a population in dire need of better treatments.",[62,30,63],"Primary Progressive Aphasia","Non-Fluent Primary Progressive Aphasia",[65,66,67],"transcranial direct current stimulation","language treatment","primary progressive aphasia","2026-04-30",{"date":35,"type":38},{"date":71,"type":38},"2024-02-13",{"date":73,"type":22},"2028-02-01",{"name":75,"class":45},"Johns Hopkins University",3,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":101,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":46},"100609830","intervention-for-communication-quality-of-life-in-primary-progressive-aphasia-100609830","NCT07219680","Intervention for Communication Quality of Life in Primary Progressive Aphasia","Intervention to Promote Communication Quality of Life for Persons With Language-Led Dementia and Their Partners: A Randomized Pilot Trial","Multi-PA","Inclusion Criteria for Persons with PPA:\n\n* A PPA (Gorno-Tempini et al., 2011) or \"PPA-plus\" (Mesulam et al., 2001) diagnosis\n* MMSE score of 15 or higher and must be able to produce single monosyllabic words intelligibly\n* Must speak English, Spanish or both languages (i.e., bilingual speakers of English or Spanish)\n* Hearing and vision adequate for participation in teleconference meetings\n* Must have a study partner available (someone who will commit to attending teleconference sessions, as needed, during assessment and treatment phases)\n\nInclusion criteria for Care Partners:\n\n* Partners must express willingness to attend and participate in assessment and treatment sessions, including those targeting dyadic communication goals\n* Partners must speak English, Spanish or both languages (i.e., bilingual speakers of English or Spanish)\n* Partner's hearing and vision should be adequate for participation in teleconference meetings\n\nThe participant and\u002For study partner must have basic experience using a computer.\n\nExclusion criteria for persons with PPA:\n\n* Other central nervous system or medical diagnosis that can account for symptoms\n* Psychiatric diagnosis that can account for symptoms",{"count":21,"type":22},[87],"NA","The goal of this clinical trial is to learn whether a personalized, multi-component, virtual speech language treatment program can improve communication and quality of life for adults with primary progressive aphasia (PPA) and their primary communication partners. The study will enroll participants who speak English and\u002For Spanish.\n\nThe main questions the study aims to answer are:\n\n* Is the telerehabilitation program feasible and acceptable for people with PPA and their study partners?\n* Do participants with PPA and study partners find treatment beneficial?\n* What patterns of treatment response are seen in participants?\n* Which outcome measures are most useful for evaluating changes in communication and quality of life?\n\nResearchers will compare participants who receive intervention immediately to participants assigned to a waitlist control group (who will receive treatment after a delay) to see whether participation in the treatment program is associated with improvements in communication and quality of life.\n\nParticipants will:\n\n* Take part in speech language therapy sessions delivered by video visit that combine restorative, compensatory, and partner-focused communication strategies. Treatment may take place after a waiting period.\n* Receive education and communication training together with their partner.\n* Complete speech, language, and cognitive assessments.\n* Complete questionnaires about communication abilities, daily functioning, and quality of life.",[90,91,92,93,94,95,96,97,98,30,99,100],"Primary Progressive Aphasia(PPA)","Semantic Dementia","Logopenic Progressive Aphasia (LPA)","Nonfluent Aphasia, Progressive","Progressive Aphasia","Semantic Variant Primary Progressive Aphasia (svPPA)","Semantic Aphasia","Logopenic Variant Primary Progressive Aphasia","Logopenic Variant of Primary Progressive Aphasia (LPA)","Nonfluent Variant Primary Progressive Aphasia (nfvPPA)","Nonfluent Progressive Aphasia",[102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118],"speech-language pathology","neurodegenerative disease","logopenic","nonfluent","semantic","script training","teletherapy","remote","multimodal communication training","partner training","augmentative and alternative communication","AAC","Communication Book","bilingual","Spanish","Hispanic","Latino","2026-04-15",{"date":121,"type":38},"2026-04-21",{"date":123,"type":38},"2026-04-01",{"date":125,"type":22},"2027-08",{"name":127,"class":45},"Maya Henry",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":46},"100353868","targeting-language-specific-and-executive-control-networks-with-transcranial-direct-current-stimulation-in-logopenic-variant-ppa-100353868","NCT03887481","Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA","Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Aphasic AD (Logopenic Variant PPA)","Inclusion Criteria:\n\n* Must be between 50-80 years of age.\n* Must be right-handed.\n* Must be proficient in English.\n* Must have a minimum of high-school education.\n* Must be diagnosed with Primary Progressive Aphasia (PPA) or dementia.\n* Participants will be diagnosed with PPA or with any of the PPA variants in specialized or early dementias clinics at Johns Hopkins University or other specialized centers in the US based on the current consensus criteria.\n* Healthy age- and education-matched controls: The investigators will include 30 healthy age- and education-matched controls, usually spouses, to maximize similarity in terms of other demographic or life-style factors that contribute to language and cognitive performance.\n\nExclusion Criteria:\n\n* People with previous neurological disease including vascular dementia (e.g., stroke, developmental dyslexia, dysgraphia or attentional deficit).\n* People with uncorrected hearing loss\n* People with uncorrected visual acuity loss.\n* People with advanced dementia or severe language impairments: Mini Mental State -Examination (MMSE)\\\u003C18, or Montreal Cognitive Assessment (MOCA)\\\u003C15, or language Frontotemporal Dementia specific - Clinical Dementia Rating (FTD-CDR)\\\u003C=2.\n* Left handed individuals.\n* People with pre-existing psychiatric disorders such as behavioral disturbances, severe depression, or schizophrenia that do not allow these people to comply or follow the study schedule and requirements such as repeated evaluation and therapy.\n\nExclusion Criteria for MRI Participation:\n\n* People with severe claustrophobia.\n* People with cardiac pacemakers or ferromagnetic implants.\n* Pregnant women.","80 Years",{"count":137,"type":22},60,[87],"AD afflicts over 5.5. million Americans and is one of the most expensive diseases worldwide. In AD the variant in which language functions are most affected are referred to as 'logopenic variant Primary Progressive Aphasia' (lvPPA). Language deficits dramatically impair communication and quality of life for both patients and caregivers. PPA usually has an early onset (50-65 years of age), detrimentally affecting work and family life. Studies have identified verbal short-term memory\u002Fworking memory (vSTM\u002FWM) as a primary deficit and cause of language impairment. In the first cycle of this award, the investigators asked the question of whether language therapy effects could be augmented by electrical stimulation. The investigators conducted the largest to-date randomized, double-blind, sham-controlled, crossover, clinical trial to determine the effects of transcranial direct current stimulation (tDCS) in PPA. The investigators found that tDCS over the left inferior frontal gyrus (L\\_IFG), one of the major language hubs in the brain, significantly enhanced the effects of a written naming and spelling intervention. In addition, findings demonstrated that tDCS modulates functional connectivity between the stimulated area and other networks (e.g. functionally and structurally connected areas), and that tDCS modulates the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). In terms of tDCS, the investigators have been identified several predictors to determine the beneficience of tDCS including (a) PPA variant, (b) initial performance on cognitive\u002Flanguage tasks, particularly vSTM\u002FWM, and (c) initial white-matter integrity and structure. These findings support the notion that tDCS benefits generalize beyond the treatment tasks and has led to the important question of the present study: How can we implement treatments to product benefits that maximally generalize to untrained but vital language\u002Fcognitive functions.\n\nTo address the above question, the investigators will test recent neuroplasticity theories that claim that the benefits of neuromodulation to language-specific areas generalize to other language functions within the language network, while neuromodulation of a domain-general\u002Fmultiple-demands area generalizes to both domain-general, executive and language functions. The two areas to be stimulated will be the supramarginal gyrus (SMG) and left dorsolateral prefrontal cortex (DLPFC) respectively. The left supramarginal gyrus (L\\_SMG) in particular, specializes in phonological processing, namely phonological verbal short-term memory (vSTM), i.e., the ability to temporarily store phonological (and graphemic) information in order. The domain of vSTM affects many language tasks (repetition, naming, syntax), which makes it an ideal treatment target and the L\\_SMG an ideal stimulation target, since generalization of tDCS effects to other language tasks is driven by the function (computation) of the stimulated area. By testing a fundamental principle of neuromodulation in a devastating neurodegenerative disorder, the investigators will significantly advance the field of neurorehabilitation in early-onset dementias.\n\nAim 1: To determine whether vSTM\u002FWM behavioral therapy combined with high definition (HD)-tDCS over the L\\_SMG will induce more generalization to language-specific tasks than to executive tasks, whereas stimulation over the LDPFC will induce equivalent generalization to both executive and language-specific tasks.\n\nAim 2: To understand the mechanism of tDCS by measuring tDCS-induced changes in network functional connectivity (FC) and GABA in the LSMG and LDPFC. The investigators will carry out resting-state functional magnetic resonance imaging (rsfMRI), (MPRAGE), diffusion-weighted imaging (DWI), perfusion imaging (pCASL), and magnetic resonance spectroscopy (MRS), before, after, and 3-months post-intervention.\n\nAim 3: To identify the neural, cognitive, physiological, clinical and demographic characteristics (biomarkers) that predict sham, tDCS, and tDCS vs. sham effects on vSTM and related language tasks in PPA. The investigators will evaluate neural (functional and structural connectivity, cortical volume, neuropeptides, and perfusion), cognitive (memory, attention, executive) and language functions, clinical (severity), physiological (sleep), and demographic (age, gender) characteristics, and the investigators will analyze the effects on vSTM and other language\u002Fcognitive outcomes immediately after intervention and at 3 months post-intervention.",[30,62],[142,143,144,145,146,67],"transcranial direct current stimulation (tDCS)","neurodegeneration","verbal short-term memory","non-fluent variant","logopenic variant","2025-09-08",{"date":149,"type":38},"2025-09-15",{"date":151,"type":38},"2022-10-15",{"date":153,"type":22},"2027-10-31",{"name":75,"class":45}]